Relying on Pharmacotherapy to Improve Motor Gains in Chronic Stroke Survivors

Inclusion Criteria: * Adults between 21 and 80 years of age. * History of ischemic stroke. * Stroke occurred at least six months prior to recruitment. * Moderate to severe UE impairment (FMA-UE score between 15 and 40) * MMSE score \>=20 and being able to safely follow three-step commands. Exclusion Criteria: * Contraindications to the pharmacotherapy (e.g., heart failure, known medication reaction or interactions with ongoing medication regimen). * Taking dual antiplatelet therapy (e.g., Aspirin+Plavix) and/or other anticoagulation medications (e.g., Eliquis, coumadin) that cannot safely be modified or discontinued (as determined by the participant's primary care physician or by the medical monitor). * Clinically significant somnolence and/or depression that would hinder active participation in motor training sessions. * Taking any medication that the study physician determines to have a significant drug-drug interaction with Telmisartan, Cilostazol, and/or Metformin. * Taking Telmisartan, Cilostazol, and/or Metformin in a dose that is different from the one used in the study and that cannot be adjusted to match the study dose (as determined by the participant's primary care physician or by the medical monitor). * Taking medications with equivalent clinical effect (e.g., BP control) to Telmisartan, Cilostazol, and/or Metformin and that cannot be replaced by Telmisartan, Cilostazol, and/or Metformin (as determined by the participant's primary care physician or by the medic…